Trial Profile
Early treatment of glucose toxicity with sitagliptin prevent progression of arteriosclerosis in cardiovascular disease patients
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 May 2016
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Coronary artery disease; Diabetes mellitus; Hyperlipidaemia
- Focus Pharmacodynamics
- Acronyms SPARC
- 30 Sep 2011 New trial record